A carregar...

Cost-utility analysis of disease-modifying drugs in relapsing-remitting multiple sclerosis in Iran

BACKGROUND: Disease-modifying drugs (DMDs) are a significant expenditure for treating multiple sclerosis (MS). However, there is limited report on assessment of the cost-utility of DMDs compared with symptom management in the presence of long-term data. This study aimed to assess the lifetime cost-u...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Imani, Ali, Golestani, Mina
Formato: Artigo
Idioma:Inglês
Publicado em: Tehran University of Medical Sciences 2012
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3829258/
https://ncbi.nlm.nih.gov/pubmed/24250871
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!